• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Dupilumab as a steroid-sparing treatment for IgG4-related disease' by Della-Torre .

作者信息

Simpson Rachel S, Lee Jason K

机构信息

Department of Allergy and Immunology, Toronto Allergists, Toronto, M5G 1E2, Canada

Department of Allergy and Immunology, Toronto Allergists, Toronto, M5G 1E2, Canada.

出版信息

Ann Rheum Dis. 2022 Feb;81(2):e25. doi: 10.1136/annrheumdis-2020-216955. Epub 2020 Feb 7.

DOI:10.1136/annrheumdis-2020-216955
PMID:32033938
Abstract
摘要

相似文献

1
Response to: 'Dupilumab as a steroid-sparing treatment for IgG4-related disease' by Della-Torre .对德拉 - 托雷的《度普利尤单抗作为IgG4相关疾病的类固醇节省治疗方法》的回应
Ann Rheum Dis. 2022 Feb;81(2):e25. doi: 10.1136/annrheumdis-2020-216955. Epub 2020 Feb 7.
2
Correspondence on: 'Dupilumab as a novel steroid-sparing treatment for IgG-related disease' by Simpson .关于辛普森所著《度普利尤单抗作为一种用于IgG相关疾病的新型类固醇节省疗法》的通信
Ann Rheum Dis. 2022 Feb;81(2):e26. doi: 10.1136/annrheumdis-2020-217010. Epub 2020 Jan 29.
3
Response to: 'Correspondence on: 'Dupilumab as a novel steroid-sparing treatment for IgG4-related disease' by Simpson ' by Ebbo .对埃博的回复：“关于辛普森的‘度普利尤单抗作为IgG4相关疾病的新型类固醇节省治疗药物’的通信” 。
Ann Rheum Dis. 2022 Feb;81(2):e27. doi: 10.1136/annrheumdis-2020-217029. Epub 2020 Mar 10.
4
Dupilumab as a steroid-sparing treatment for IgG4-related disease.度普利尤单抗作为IgG4相关性疾病的一种激素替代治疗药物。
Ann Rheum Dis. 2022 Feb;81(2):e24. doi: 10.1136/annrheumdis-2020-216945. Epub 2020 Jan 14.
5
Dupilumab as a novel steroid-sparing treatment for IgG4-related disease.度普利尤单抗作为一种用于IgG4相关疾病的新型类固醇节省疗法。
Ann Rheum Dis. 2020 Apr;79(4):549-550. doi: 10.1136/annrheumdis-2019-216368. Epub 2019 Dec 19.
6
A case of IgG4-related dacryoadenitis and sialoadenitis remitted by dupilumab monotherapy.1例经度普利尤单抗单药治疗缓解的IgG4相关性泪腺炎和涎腺炎病例。
Rheumatology (Oxford). 2024 May 3;63(6):e188-e189. doi: 10.1093/rheumatology/kead680.
7
[A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY].[1例经小唾液腺活检证实对度普利尤单抗有反应的IgG4相关性疾病]
Arerugi. 2024;73(9):1158-1162. doi: 10.15036/arerugi.73.1158.
8
Response to : 'Interleukin-4 as a emerging target for IgG4-related disease' by Akiyama .对秋山所著《白细胞介素-4作为IgG4相关疾病的新兴靶点》的回应
Ann Rheum Dis. 2022 Feb;81(2):e29. doi: 10.1136/annrheumdis-2020-216977. Epub 2020 Feb 7.
9
Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report.度普利尤单抗辅助治疗因哮喘而复杂化的类固醇依赖型 IgG4 相关疾病患者：一例报告。
J Asthma. 2022 Dec;59(12):2395-2401. doi: 10.1080/02770903.2021.2022158. Epub 2021 Dec 31.
10
IgG4-related disease administered dupilumab: case series and review of the literature.IgG4 相关疾病应用度普利尤单抗：病例系列和文献复习。
RMD Open. 2023 Mar;9(1). doi: 10.1136/rmdopen-2023-003026.